Suppression of FVIII-specific Memory B Cells by Regulatory T Cells Expressing BARs
ISTH Academy. Zhang A. Jul 10, 2019; 274138; OC 76.2 Topic: Coagulation Factors & Inhibitors
Ai-Hong Zhang
Ai-Hong Zhang
Access to Reserved content is available to attendees of the Congress until the end of the year and always available for full ISTH members.

Click here to join ISTH or renew your membership.

Discussion Forum (0)
Rate & Comment (0)

OC 76.2

Suppression of FVIII-specific Memory B Cells by Regulatory T Cells Expressing BARs

A.-H. Zhang, S.H. Venkatesha, D.W. Scott
Uniformed Services University of the Health Sciences, Bethesda, United States

Main Topic: Coagulation and Anticoagulation
Category: Coagulation Factors & Inhibitors

Background: Anti-FVIII neutralizing antibody (inhibitor) formation poses significant obstacles for optimal treatment of hemophilia A. We have recently shown that human regulatory T cells (Tregs) expressing a FVIII-domain as a chimeric B-cell antibody receptor (BAR) prevented anti-FVIII antibody formation in hemophilic mice by directly suppressing B cells (Zhang AH, J Immunol. 201:1434-1441, 2018).
Aims: In this study, we sought to determine whether FVIII-specific memory B cells could be suppressed by the FVIII BAR Tregs.
Methods: To test this in vitro, we used plasmablast-depleted splenocytes from FVIII immunized hemophilia mice to serve as the source of FVIII-specific memory B cells.
Results: Co-culture of CD138- splenocytes with FVIII antigen in the presence of FVIII A2-domain BAR human Tregs completely blocked the development of FVIII-specific antibody forming cells (ASC). In addition, FVIII A2-BAR human Tregs efficiently suppressed FVIII-specific ASC formation in the presence of anti-FVIII antibodies in vitro. Similar results were obtained when BAR-expressing murine Tregs were used.
Conclusions: In conclusion, we demonstrated in vitro that FVIII BAR Tregs suppress FVIII-specific memory B cells activity. The efficacy of FVIII BAR Tregs on FVIII-specific memory B cells will be further tested in vivo by adoptive transfer of FVIII-specific memory B cells in syngeneic hosts. Supported by a Bayer Hemophilia Grant [AHZ] and NIH HL126727 [DWS].

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies